Feb 14
Prioritization/Triage: High-level assessment of key characteristics of source documents to determine cases of critical importance/urgency prior to data processing to ensure the case is processed in the appropriate timeline. Prioritization is typically based on factors such as death or life-threatening events, case seriousness, country-specific reporting timelines, association (relatedness), and/or expectedness. Once cases have been prioritized, they are assigned to an appropriate workflow/person.
In 2020:
60% of respondents were applying at least some level of automation.
40% of respondents reported no automation of this ICSR process step.
In 2021:
83% of respondents were applying at least some automation.
17% of respondents reported no automation of this ICSR process step.
Related Blog Posts
Are Pragmatic Trials The Patient Recruitment Solution We’ve Been Looking For?
The age-old problem for clinical research has been the ability to recruit patients. Many clinical research professionals have tried to crack this nut, whether with technology or partnerships or both. Let’s not forget the height of DCTs during the pandemic, which served their purpose but appear to have lost luster in the last few years.…
Solving the Clinical Trial Data Problem
In a new LinkedIn article, Janice Chang, CEO of TransCelerate, and Nicholas Brooke, CEO of The Synergist & PFMD, outline how efforts like the Clinical Trial Data Network, supported by TransCelerate through technical expertise and industry-vetted solutions from our Digital Data Flow initiative, aim to make clinical trial information more structured, connected, and accessible across…
The Clinical Trial Enterprise: Can AI Fix It?
Artificial Intelligence (AI) is reasonably well established in discovery and preclinical research, with success in areas such as target identification and molecular modeling. However, in clinical development, adoption has been fragmented and challenging to embed across the lifecycle. Read the full article by Rob DiCicco from Drug Discovery News here.